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Background: The mechanisms that can restore biological activity of mutant p53 are an area of high interest given
that mutant p53 expression is observed in one third of prostate cancer. Here we demonstrate that Id4, an HLH
transcriptional regulator and a tumor suppressor, can restore the mutant p53 transcriptional activity in prostate
cancer cells.
Methods: Id4 was over-expressed in prostate cancer cell line DU145 harboring mutant p53 (P223L and V274F) and
silenced in LNCaP cells with wild type p53. The cells were used to quantitate apoptosis, p53 localization, p53 DNA
binding and transcriptional activity. Immuno-precipitation/-blot studies were performed to demonstrate interactions
between Id4, p53 and CBP/p300 and acetylation of specific lysine residues within p53.
Results: Ectopic expression of Id4 in DU145 cells resulted in increased apoptosis and expression of BAX, PUMA and
p21, the transcriptional targets of p53. Mutant p53 gained DNA binding and transcriptional activity in the presence
of Id4 in DU145 cells. Conversely, loss of Id4 in LNCaP cells abrogated wild type p53 DNA binding and
transactivation potential. Gain of Id4 resulted in increased acetylation of mutant p53 whereas loss of Id4 lead to
decreased acetylation in DU145 and LNCaP cells respectively. Id4 dependent acetylation of p53 was in part due to
a physical interaction between Id4, p53 and acetyl-transferase CBP/p300.
Conclusions: Taken together, our results suggest that Id4 regulates the activity of wild type and mutant p53. Id4
promoted the assembly of a macromolecular complex involving CBP/P300 that resulted in acetylation of p53 at
K373, a critical post-translational modification required for its biological activity.
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Id (Inhibitor of differentiation) proteins (Id1, Id2, Id3
and Id4) are dominant negative regulators of basic helix
loop helix transcription factors such as TCF3 [1,2]. Apart
from blocking the general bHLH-DNA (E-box response
element) interactions, the Id1, 2 and 3 proteins also
interact with several non-bHLH proteins such as CASK,
ELK1, 3 and 4, GATA4, caveolin, CDK2, PAX2, 5 and 8,
Rb and related pocket proteins and ADD1 ([1,2] and
public databases). Currently, the non-bHLH interaction
partners for Id4 are not known. Id proteins can thus
control many cellular processes such as cell growth, dif-
ferentiation, and apoptosis [3], through specific bHLH
and non-bHLH interactions.* Correspondence: jchaudhary@cau.edu
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reproduction in any medium, provided the orId proteins in general, promote proliferation and inhibit
differentiation with few exceptions such as Id2 and Id4
that can also promote differentiation in some organ sys-
tems. Id4 promotes differentiation of osteoblasts [4], ad-
ipocytes [5], neurons [6], but inhibits oligodendroglial
differentiation [7] by blocking the transcriptional activity
of bHLH protein Olig1/2.
Majority of studies have demonstrated tumor suppressor
activity of Id4 which is largely based on the evidence
that it is epigenetically silencing in cancers such as
leukemia [8], breast [9,10], colorectal [11] mouse and
human CLL (chronic lymphocytic leukemia [12]) and
gastric cancer [13]. High Id4 expression is observed in
bladder [14] and rat mammary gland carcinomas, [15],
whereas chromosomal translocation of Id4 (t(6;14)(p22;
q32)) was found in B-cell acute lymphoblastic leukemia
[16] and B-cell precursor acute lymphoblastic leukemial Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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promoter activity.
Decreased Id4 expression with increasing grade of pros-
tate cancer is also associated with Id4 promoter hyper-
methylation [18,19]. The prostate cancer cell line DU145
also lacks Id4 expression due to promoter hypermethyla-
tion whereas LNCaP cells express Id4 [20]. Interestingly,
DU145 cells also harbor mutant p53 with extended half-
life, a property associated with mutated forms of p53 [21].
The p53 mutants (P223L and V274F) in DU145 cells are
rare but located within the DNA binding domain (DBD
94-292) known to abrogate p53 activity [22,23]. The
V274F mutation in DU145 cells is next to R273H/C/L/P,
a DNA contact and one of the most highly mutated
amino acid in p53 [23]. Both these amino acids (274°F
and 273H) are within the conserved region of p53 beta
strand S10 whereas 223 L lies in the outer loop [24].
Studies have shown that some but not all p53 mutations
maintain transactivation potential for some promoters
(e.g. CDKN1a) but not others (e.g. BAX, PUMA and
Pig3) [25]. Likewise, the mutant p53 in DU145 also
lacks the ability to trans-activate CDKN1A [21]. We
have shown that ectopic expression of Id4 in DU145
cells triggers apoptosis and CDKN1A dependent cell
cycle arrest [20]. CDKN1A being a prototype p53 tran-
scriptional target prompted us to investigate whether
Id4 promoted mutant p53 transcriptional activity in DU145
cells. The results presented in this study demonstrate that
Id4 can promote the binding of mutant p53 to its response
element on the p21 promoter and other p53 responsive
apoptotic target genes such as BAX and PUMA. At the
mechanistic level we demonstrate that Id4 recruits acetyl
transferase CBP/p300 to promote acetylation of p53. Thus,
mutant p53 in DU145 may retain conformational flexi-
bility which upon post-translational modification could
achieve wild type activity. Studies reported earlier have
indeed shown that PCAF dependent acetylation can re-
store wild type activity of certain p53 mutants (G245A
and R175H) [26]. Since more than one third of prostate
cancers harbor mutant p53 [27,28] and majority of pros-
tate cancers also lack Id4 [18,19]; hence physiological
mechanisms involved in the transition of mutant p53 to
wild type activity are of clinical relevance.
Materials and methods
Id4 over-expression and silencing in prostate cancer cell lines
LNCaP, DU145 and PC3 prostate cancer cell lines were
purchased from ATCC and cultured as per ATCC recom-
mendations. Human Id4 was over-expressed in DU145
cells as previously described [20]. Id4 was stably silenced
in LNCaP cells using gene specific shRNA retroviral
vectors (Open Biosystems #RHS1764-97196818,-97186620
and 9193923 in pSM2c, termed as Id4shRNA A, B and
C respectively). The cells transfected with non-silencingshRNA (RHS1707) was used as control. Transfections
and selection of transfectants (puromycin) were per-
formed as suggested by the supplier. Successful Id4 gene
silencing was confirmed by qRT-PCR and Western blot
analysis.
Western blot analysis and Co-immunoprecipitation
30 μg of total protein, extracted from cultured prostate
cancer cell lines using M-PER (Thermo Scientific) was
size fractionated on 4-20% SDS-polyacrylamide gel (5%
for CBP/p300 western blotting). The SDS-gel was subse-
quently blotted onto a nitrocellulose membrane (Whatman)
and subjected to western blot analysis using respective
protein specific antibodies (Additional file 1: Table A1).
After washing with 1× PBS, 0.5% Tween 20, the mem-
branes were incubated with horseradish peroxidase (HRP)
coupled secondary antibody against rabbit IgG and visual-
ized using the Super Signal West Dura Extended Dur-
ation Substrate (Thermo Scientific) on Fuji Film LAS-3000
Imager.
To detect the protein-protein interactions, co-immuno-
precipitation was performed using protein A coupled to
magnetic beads (Protein A Mag beads, GenScript) as per
manufacturer’s instructions. Briefly, protein specific IgG
(anti-p53 or-Id4, Additional file 1: Table A1) was first
immobilized to Protein A Mag Beads by incubating over-
night at 4°C. To minimize the co-elution of IgG following
immuno-precipitation, the immobilized IgG on protein
A mag beads was cross-linked in the presence of 20 mM
dimethyl pimelimidate dihydrochloride (DMP) in 0.2 M
triethanolamine, pH8.2, washed twice in Tris (50 mM
Tris pH7.5) and PBS followed by final re-suspension and
storage in PBS. The cross-linked protein specific IgG-
protein A-Mag beads were incubated overnight (4C) with
freshly extracted total cellular proteins (500 μg/ml). The
complex was then eluted with 0.1 M Glycine (pH 2-3)
after appropriate washing with PBS and neutralized by
adding neutralization buffer (1 M Tris, pH 8.5) per 100 μl
of elution buffer.
Chromatin immuno-precipitation (ChIP) assay
Chromatin immuno-precipitation was performed using
the ChIP assay kit (Millipore, Billerica, MD) as per
manufacturer’s instructions. The chromatin (total DNA)
extracted from cells was sheared (Covaris S220), subjected
to immuno-precipitation with p53, normal IgG or RNA
pol II antibodies (Additional file 1: Table A1), reverse
cross linked and subjected to qRT-PCR in Bio-Rad CFX.
The previously published CHiP primer sets spanning the
consensus p53 response element sites in the promoters
of BAX [29], p21 [29], PUMA [30] and MDM2 [29]
were used (Additional file 2: Table A2). The first intron
of TCF3 (E2A) was used a negative control for p53 ChIP
assays (Additional file 2: Table A2). The lack of consensus
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the TCF3 intron 1 sequence to TRANSFAC database
search [31].
Quantitative real time PCR (qRT-PCR)
qRT-PCR was performed as described previously using
gene specific primers (Additional file 2: Table A2) on RNA
purified from cell lines [32].
Electrophoretic mobility shift assay (EMSA)
The nuclear proteins from respective cell lines were pre-
pared using the nuclear extraction kit from Affymetrix
(AY2002) as per manufacturer’s instructions. 1 μg of nuclear
proteins were used in an EMSA reaction using Biotin end
labeled p53 double stranded oligonucleotide (Affymerix,
AY1032, p53(1) EMSA kit containing the p53 response
element [29]: 5′-TAC AGA ACA TGT CTA AGC ATG
CTG GGG ACT. The biotin end labeled mutated p53 re-
sponse element (5′-TAC AGA ATC GCT CTA AGC ATG
CTG GGG ACT) was used as a negative control. The
nuclear proteins and labeled oligonucleotide or excess
unlabeled oligonucleotide were incubated for 20mins at
room temperature, separated on 5% non-denaturing poly-
acrylamide gel and transferred onto nitrocellulose mem-
brane and detected following manufacturer’s instructions.
The EMSA using LNCaP cells with wild type p53 and
p53 null PC3 was used as positive and negative controls
respectively.
P53 activity assay
p53 DNA binding activity and quantitation on nuclear
extracts was performed by capturing p53 with double
stranded oligonucleotides containing a p53 consensus
binding site immobilized in a 96 well format (TF-Detect
p53 Assay, Genecopoeia) followed by detection with p53
specific antibody in a sandwich ELISA based format as
per manufacturer’s instructions (essentially a quantitative
super-shift assay).
Transient transfections and reporter gene assay
Cells were cultured in 96-well plates to 70-80% con-
fluency and transiently transfected by mixing either
PG13-luc (containing 13 copies wt p53 binding sites [33],
Addgene) or MG15-luc (containing 15 mutant p53 bind-
ing sites [33], Addgene) with pGL4.74 plasmid (hRluc/TK:
Renilla luciferase, Promega) DNA in a 10:1 ratio with
FuGENE HD transfection reagent (Promega) in a final
volume of 100 ul of Opti-MEM and incubated for 15 min
at room temperature. The transfection mix was then
added to the cells. After 24 h, the cells were assayed for
firefly and Renilla luciferase activities using the Dual-Glo
Luciferase reporter assay system (Promega) in LUMIstar
OPTIMA (MHG Labtech). The results were normalized
for the internal Renilla luciferase control.Immuno-cytochemistry
Cells were grown on glass chamber slides up to 75%
confluency. The slides were then washed with PBS (3x)
and fixed in ice cold methanol for 10 min at room
temperature and stored at−20°C until further use. Before
use, the slides were equilibrated at room temperature,
washed with PBS (5 min ×3), blocked with 1%BSA in
PBST for 30 min at room temp and Incubated overnight
(4C) with primary antibody (1% BSA in PBST, Additional
file 1: Table A1). The slides were then washed in PBS
and incubated with secondary antibody with fluorochrome
conjugated to DyLight (Additional file 1: Table A1) in 1%
BSA for 1 hr at room temp in dark. The slides were sub-
sequently washed again and stained in DAPI (1 μg/ml)
for 1 min and mounted with glycerol. Images were
acquired by Zeiss fluorescence microscope through Axio-
vision software.
Apoptosis assay and mitochondrial membrane
potential (MMP)
Apoptosis and MMP was quantitated using Propidium
Iodide, Alexa Fluor 488 conjugated Annexin V (Molecular
Probes) and dual-sensor MitoCasp (Cell Technology)
respectively, as described previously [34].
Statistical analysis
Quantitative real time data was analyzed using the ΔΔCt
method. The CHiP data was analyzed using % chromatin
(1%) as input (Life Technologies). Within group Student’s
t-test was used for evaluating the statistical differences
between groups.
Results
Generation of Id4 expressing and non-expressing prostate
cancer cell lines
Id4 is undetectable in DU145 cells due to promoter
hyper-methylation [18]. In contrast, Id4 is expressed in
LNCaP cells. These two cell lines were used to either
over-express (DU145 + Id4) or silence (LNCaP-Id4) Id4.
Three different retroviral shRNA vectors (vectors A, B
and C) were used to silence Id4 (Figure 1, vector B had
no effect on Id4 levels, not shown) in LNCaP cells. The
stable knockdown of Id4 in LNCaP cells using shRNA
vector A (LNCaP-Id4), Id4 over-expressing DU145 cells
(DU145 + Id4, Figure 1C) and their respective vector only
transfected cells were used for all subsequent experiments.
Id4 promotes apoptosis
A significant increase in apoptotic cells (Annexin V posi-
tive) was observed in DU145 + Id4 (26.7 ± 3.2%, P < 0.001,
Figure 2A) cells as compared DU145 cells (7.1 ± 1.2%,
Figure 2A) whereas number of cells undergoing apop-
tosis decreased in LNCaP-Id4 (7.6 ± 1.9%) as compared
to LNCaP (19.3 ± 3.6%) cells (Figure 2A). Apoptosis in
Id4
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Figure 1 Stable knockdown of Id4 by retroviral shRNA in LNCaP cells (retroviral vectors A and C) and stable over-expression of hId4 in
Du145 cells. A. Real time quantitative polymerase chain reaction for Id4 expression in LNCaP (NS, non-specific) following transfection with Id4 shRNA
vectors A and C and non-silencing shRNA (NS) (***: P < 0.001). B. Western blot analysis of Id4 expression in LNCaP cells with non-specific shRNA (NS)
and Id4 specific shRNA (−Id4, vector A). C: Immuno-cytochemical analysis of stable knockdown of Id4 expression in LNCaP cells (LNCaP-Id4, vector A)
as compared to cells with non-specific shRNA (LNCaP + NS). The red staining indicates Id4 expression (DyLight 594). Id4 expression in DU145
cells stably transfected with Id4 expression vector (DU145 + Id4) as compared to DU145 cells transfected with empty vector (DU145 + NS). The
green staining represents Id4 (DyLight 488). DAPI was used to stain the nuclei (blue) in both LNCaP and DU145 cells. Representative images
are shown.
Knowell et al. Molecular Cancer 2013, 12:161 Page 4 of 13
http://www.molecular-cancer.com/content/12/1/161DU145 + Id4 cells was accompanied by decreased mito-
chondrial membrane potential (MMP, 36 ± 4.94%, Figure 2B)
whereas decreased apoptosis in LNCaP-Id4 cells was
associated with increased MMP (82.3 ± 10.21%) as com-
pared to DU145 (71.3 ± 9.30%) and LNCaP (59.4 ± 6.60%)
respectively (Figure 2B). These results led us to conclude
that Id4 promotes apoptosis through changes in MMP
that eventually promotes cytochrome c release from the
mitochondria [35].
Increased BAX expression and/or PUMA dependent
dissociation of BAX from Bcl-2 promotes translocation
of BAX to mitochondria resulting in decreased mitochon-
drial membrane potential [36]. The expression of pro-
apoptotic BAX and PUMA increased in DU145 + Id4
cells whereas a corresponding decrease in BAX and
PUMA was observed in LNCaP-Id4 cells at the protein
(Figure 2C) and transcript (Figure 2D) level as com-
pared to DU145 and LNCaP cells respectively (Figure 2C
and D). These results implicated the role of Id4 in pro-
moting apoptosis through increased expression of BAX
and PUMA. Activation of BAX in response to apoptotic
stimuli is characterized by translocation and multimeri-
zation on the mitochondrial membrane surface resulting
in exposure of an amino terminal epitope recognized by
the conformation specific monoclonal antibody BAX 6A7[37]. Co-localization of BAX (BAX 6A7 antibody) with
mitochondrial PDH (pyruvate dehydrogenase) demon-
strated that BAX undergoes conformational change and
translocates to the mitochondria in DU145 + Id4 and
LNCaP cells (Figure 2E) but not in DU145 and LNCaP-Id4
cells possibly due to undetectable levels of BAX (Figure 2C).
Next, we investigated the expression of CDKN1A (p21)
which is also a well-characterized p53 responsive gene
[38]. The p21 protein and transcript expression increased
significantly in DU145 + Id4 cells as compared to DU145
(Figure 2C and D, 9 fold as compared to DU145). The p21
protein expression in LNCaP-Id4 cells also decreased as
compared to LNCaP, but intriguingly the levels of p21
transcript (mRNA) were similar between LNCaP-Id4
and LNCaP cells.
Id4 alters expression and cellular localization of p53
Both BAX and PUMA are also transcriptional targets
of the tumor suppressor protein p53 [39]. Reduced apop-
tosis in part due to loss of BAX and PUMA expression
in LNCaP-Id4 cells was associated with low p53 expres-
sion as compared to LNCaP cells (Figure 3A). A similar
relationship between Id4 and p53 expression was not
observed in DU145 cells. Unlike wt-p53 in LNCaP cells,
the DU145 cells harbor a mutant p53 (mut-p53). The
PUMA
GAPDH
































































Figure 2 Id4 promotes apoptosis by regulating mitochondrial membrane potential and the expression of pro-apoptotic genes. A: percent
cells undergoing apoptosis was determined by propidium iodide and Annexin V staining followed by flow cytometery. Significant increase in
apoptosis (***: P < 0.001) was observed in DU145 cells over-expressing Id4 (D + Id4) when compared with DU145 cells alone (D). A significant decrease
in apoptosis was observed in LNCaP cells that lacked Id4 (L-Id4) as compared to LNCaP cells (L, ***: P < 0.001). B. Percent cells with high mitochondrial
membrane potential (Gated, FL2 > 100 fluorescence units). In the presence of Id4 (D + Id4 and L), the mitochondrial membrane potential decreased as
compared to the corresponding cells that lack Id4 (D and L-Id4). (***: P < 0.001–L vs. L-Id4 and D vs. D + Id4). C. Western blot analysis of p21,
BAX, conformation specific BAX (BAX6A7) and PUMA in D, D + Id4, L and L-Id4 cells. GAPDH was used as loading control. Representative western
blots of three different experiments are shown. D. Real time quantitative analysis of p21, BAX and PUMA expression in D, D + Id4, L and L-Id4
cells. The mean ± SEM of three experiments in triplicate is shown. The ΔΔCt (normalized to GAPDH) between D and D + Id4 (D normalized to 1,
designated as “a”) and between L and L-Id4 (L normalized to 1, designated as “b”) is shown (*: P < 0.001). E. Immuno-cytochemical analysis
demonstrating co-localization of conformation specific BAX (using BAX 6A7 antibody) with mitochondrial pyruvate dehydrogenase (PDH).
Blue: DAPI, red: PDH, green: BAX 6A7 and yellow: co-localization of BAX and PDH (observed only in LNCaP and DU145 + Id4 panels. Representative
images from three different experiments are shown.
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binding domain resulting in a transcriptionally inactive
form of p53 [22]. Mut-p53 protein generally accumu-
lates at high levels due to loss of regulatory mechanisms
[40] as seen in DU145 cells (Figure 3A and B, 12 fold
higher as compared to LNCaP cells). Surprisingly, we
observed decreased levels of mut-p53 in DU145 + Id4
cells (Figure 3A). These results are significant especially
in context of increased expression BAX and PUMA in
DU145 + Id4 cells in spite of low mut-p53 expression.
We reasoned that one of the mechanisms by which
mut-p53 could up-regulate BAX/PUMA expression could
be through gain of transcriptional activity in DU145 + Id4cells. Immuno-cytochemical localization of p53 also
revealed that mut-p53 is localized to the nucleus and
cytoplasm in DU145 (Figure 3B, DU145, arrows) cells
but is primarily nuclear in DU145 + Id4 cells (Figure 3B,
DU145 + Id4, arrows). Previous studies have also shown
a predominant cytoplasmic staining of mutant p53 in
prostate cancer whereas wt-p53 is primarily nuclear [41].
Id4 restores mutant p53 DNA binding and
transcriptional activity
An EMSA with canonical p53 DNA response element
was used to determine the DNA binding ability of wt-
(LNCaP) and mut-p53 (DU145). LNCaP cells with wt-
























Figure 3 Id4 regulates p53 expression and cellular localization. Analysis of p53 protein (A) expression in L, L-Id4, D and D + Id4 cells. The
western blot analysis shown in panel A is the representative of three different experiments. B. Immuno-cytochemical localization of p53 in L, L-Id4, D
and D + Id4 cells. Nuclear and cytoplasmic (arrows) expression of p53 is clearly evident in L, L-Id4 and D cells. Whereas p53 is primarily nuclear
in D + Id4 cells (arrows). Red: p53, Blue: DAPI. Representative images are shown.
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of lower intensity was observed in LNCaP-Id4 as com-
pared to LNCaP cells perhaps due to lower expression
of wt-p53 (Figure 3A and B). A distinct gel shift was ob-
served in the presence of DU145 + Id4 nuclear extracts,
but no gel shift was observed with DU145 nuclear ex-
tracts, suggesting that mut-p53 in the absence of Id4
lacks DNA binding activity. Increased binding of p53 to
its cognate response element immobilized on a 96 well
plate followed by detection with p53 specific antibody
was also observed in LNCaP and DU145 + Id4 that was
significantly higher as compared to LNCaP-Id4 and DU145
cells respectively (Figure 4B). In a functional transcriptionalassay using a p53 response element (wt-p53RE) luciferase
reporter plasmid, the relative p53 luciferase activity de-
creased significantly in LNCaP-Id4 cells as compared to
LNCaP cells (normalized to 1, Figure 4C), which is con-
sistent with the expression of p53 in these cell lines. Sur-
prisingly, mut-p53 in DU145 + Id4 cells demonstrated
high luciferase activity as compared to DU145 (normal-
ized to 1, wt-p53RE). The mutant p53 luciferase plasmid
(mt-p53RE) used as a negative control, as expected, did
not result in significant luciferase activity. In context of
using LNCaP as a positive control, our results strongly
suggested that mut-p53 gains DNA binding and tran-
scriptional activity in the presence of Id4 that is in part
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Figure 4 Id4 promotes DNA binding and transcriptional activity of wild type and mutant p53. A. EMSA with p53 consensus DNA binding
response element with nuclear extracts from LNCaP (L), LNCaP-Id4 (L-Id4), DU145 (D), DU145 + Id4 (D + Id4) and PC3 cells. Nuclear extracts from
PC3 cells, null for p53 and LNCaP cells with wild type p53 were used as negative and positive controls respectively for binding to wild type p53
response element. Excess unlabeled (EU) wild type p53 response element was used to monitor non-specific binding. The biotin labeled mutant
p53 response element (mt) incubated with nuclear extracts from LNCaP cells (L +mt) was used to demonstrate specificity of EMSA. B. Quantitative
p53 DNA binding in a sandwich ELISA based system. P53 was captured by double stranded oligonucleotide with p53 response element immobi-
lized on a 96 well plate. The captured p53 was detected using p53 antibody by measuring the intensity at 450 nm using HRP coupled secondary
antibody. C. The p53 transcriptional activity as determined by transiently transfecting cell lines as indicated above with p53 response element
driven luciferase reported plasmid (wt-p53RE). The data is normalized to Renilla luciferase. The mutant p53 luciferase reporter plasmid was used
as a negative control (mt-p53RE). The p53-luciferase reporter activity in LNCaP-Id4 (L-Id4) was normalized to LNCaP (L) and that of DU145 + Id4
(D + Id4) with DU145 (D). The data from 3 different experiments in triplicate is expressed as mean + SEM (*: P < 0.001).
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through siRNA was used to further clarify the role of
mutant p53 in DU145. However, siRNA based p53 silen-
cing led to massive apoptosis in DU145 [42].
Id4 enhances p53 binding to target promoters
Real time quantitative PCR analysis on Chromatin immuno-
precipitated (ChIP) DNA with p53 antibody demonstrated
the binding of wt-p53 to its respective response elements on
BAX (Figure 5A), p21 (Figure 5B) and PUMA (Figure 5C)
promoters in LNCaP cells. The enrichment of p53 on the
respective promoters (p21, BAX and PUMA) was specific
since we did not observe a similar enrichment on intron 1
of TCF3 gene that lacks a consensus p53 response element
as determined TRANSFAC database search [31] (Figure 5D).
The decreased p53 expression in LNCaP-Id4 correlated withdecreased binding to its respective promoter elements on
BAX, p21 and PUMA promoters (P < 0.001). As anticipated,
in DU145 cells no significant binding of mutant p53 was
observed on p21, PUMA and BAX promoters. However,
in DU145 + Id4 cells, a significant increase in the bind-
ing of mut-p53 as compared to DU145 cells was ob-
served on BAX, p21 and PUMA promoters.
RNA polymerase II (Pol II) was constitutively bound
to the PUMA (Figure 5G) and p21 promoters (Figure 5F)
in LNCaP and LNCaP-Id4 cells lines suggesting that bind-
ing of p53 was required to initiate transcription form these
promoters but not for the assembly of the transcription
pre-initiation complex. On BAX promoter, a significant
decrease in the enrichment of RNA Pol II promoter was
observed in LNCaP-Id4 cells as compared to LNCaP cells,





















































































































Figure 5 Chromatin immuno-precipitation assay demonstrating the enrichment of p53 (A, B, C and D) and RNA polymerase II
(RNA Pol II, E, F, G and H) on the BAX, p21 and PUMA promoters. The intron 1 region of TCF3 gene was used as a negative control
for p53 ChIP studies (D). The data is expressed as percent input is mean ± SEM of three experiments in triplicate (a: between L and L-id4
and b: between D and D + Id4, *: P < 0.001, BD: Below Detection)
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cells (Figure 5E). These results suggested that binding of
p53 may be required for recruitment RNA Pol II complex
on BAX promoter in these two cell lines.
Id4 promotes p53 dependent MDM2 expression
Incidentally, p53 also regulates MDM2, (an E3 ubiquitin
ligase involved in p53 protein degradation) expression in
a highly complex manner. In this study we focused on
investigating whether MDM2 expression is regulated in
a p53 dependent manner at the promoter level, rather
than on interaction between wt- and mut-p53 with MDM2
at the protein level. Unpredictably, MDM2 protein expres-
sion was higher in LNCaP-Id4 (1.8 ± 0.46 fold, Figure 6A)
cells as compared to LNCaP cells (Figure 6A and semi
quantitation in lower panel) in spite of lower p53 ex-
pression (Figure 3A and B). The expression in DU145
cells (2.1 ± 0.19 fold) was comparable to LNCaP-Id4
cells (Figure 6A). However, MDM2 expression was lower
in DU145 + Id4 (0.9 ± 0.16) cells as compared to DU145
but was comparable to LNCaP cells (normalized to 1).
MDM2 expression is regulated by a p53 response element
located within the P2 promoter in intron 1 (Figure 6B)
[43]. The alternative, P1 promoter, upstream of exon1 isgenerally considered p53 independent [44]. Both P1 and
P2 transcripts are however translated from the common
start site in exon 2. Abundance of P1 and P2 transcripts
was then performed to understand whether MDM2 ex-
pression is regulated in a p53 dependent (P2) or inde-
pendent (P1) manner. The results suggested that MDM2
expression in LNCaP cells is primarily due to transcription
from the P2 promoter in part due to the binding of p53
(Figure 6D), whereas in LNCaP-Id4 cells, MDM2 ex-
pression is a result of activation from the P1 promoter
(Figure 6C). In DU145 cells, the P1 promoter was active
as compared to P2, but in DU145 + Id4 cells, the p53
dependent (Figure 6D) P2 promoter was transcription-
ally active (Figure 6C). These results suggested that the
regulation of MDM2 expression is highly complex and
that in cells lacking Id4 (LNCaP-Id4 and DU145), the
P1 promoter is transcriptionally active whereas in cells
with Id4 (LNCaP and DU145 + Id4) the p53 dependent
P2 promoter is active (Figure 6D).
Id4 Recruits CBP/p300 to promote p53 acetylation
Acetylation, independent of phosphorylation status, pro-
motes p53 stabilization and transcriptional activity but
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Figure 6 Expression of MDM2 and its transcriptional regulation. A. MDM2 immuno blot in cells with (L and D + Id4) and without Id4
(L-Id4 and D). GAPDH was used as loading control. Representative data from three different experiments is shown. The bottom panel is
semi-quantitative analysis of fold change in MDM2 expression relative to LNCaP (L) and normalized to GAPDH (mean ± SEM, *: P < 0.001,
compared to L). B. Schematic of MDM2 promoter organization. MDM2 is transcribed from two independent promoters P1 and P2 but both
the transcripts are translated from a common start site in exon2. P1 promoter is p53 independent whereas P2 promoter is p53 dependent
due to a p53 response element in intron 1 (p53RE). Specific primers were used to determine the transcript abundance of P1 (p53 independent) and P2
(p53 dependent) transcripts. C. P1 and P2 transcript abundance with Real time quantitative PCR analysis in cell lines expressed as fold change from
three different experiments in triplicate (mean ± SEM). The expression is first normalized to GAPDH and then to P1 transcript in L and D cells set to 1
(comparison between L and L-Id4 and between D and D + Id4, a: P < 0.001 as compared to P1 transcript b: P < 0.001 compared to P2 transcript).
D. Chromatin immuno-precipitation assay demonstrating the binding of p53 to its respective response element in the MDEM2 P2 promoter (intron 1).
Data is expressed as mean + SEM of three different experiments performed in triplicate (mean + SEM, *: P < 0.001).
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forms p53 can restore the DNA binding activity [26].
These studies led us to explore whether Id4 promotes
acetylation of mut-p53 in DU145 + Id4 cells. The total
p53 protein was first immuno-precipitated and then
immuno-blotted with acetylated lysine antibody. Increased
global p53 lysine acetylation was observed in DU145 + Id4
and LNCaP cells as compared to LNCaP-Id4 and DU145
cells (Figure 7A). In p53, K320 is acetylated by PCAF
and promotes p53-mediated activation of cell cycle
arrest genes such as p21 [46]. In contrast, acetylation
of K373 leads to hyper-phosphorylation of p53 NH2-
terminal residues and enhances the interaction with
promoters for which p53 possesses low DNA binding
affinity, such as those contained in pro-apoptotic genes,
BAX and PUMA [46]. The results shown in Figure 7Ademonstrated a significant increase in K373 acetylation
in DU145 + Id4 cells whereas no significant change
was observed between LNCaP and LNCap-Id4 cells.
The K320 expression was also significantly higher in
DU145 + Id4 and LNCaP cells as compared to DU145
and LNCaP-Id4 cells. These results provided evidence
that Id4 is involved in promoting acetylation of specific
residues in wt-and mut-p53 that promotes its binding to
respective response elements. The increased K320 acetyl-
ation in DU145 + Id4 cells clearly is consistent with the
study by Parez et al. [26] in which the authors demon-
strated acetylation at this specific residue restores mutant
p53 biological activity. We were however intrigued with a
significant increase in the expression of acetylated K373
in DU145 + Id4 cells. Acetylation at K373 is CBP/P300
dependent [47]. We hypothesized that if CBP/P300 is
L L-Id4  D D+Id4IP: p53
IB: Global K-Ac






L L-Id4  D D+Id4IP: Id4
IB: p53
Input-Id4
IB: p53 K-320 Ac
Figure 7 Acetylation of p53 and interaction with CBP/p300 and
Id4. A. p53, immuno-precipitated from cell lines was blotted with
antibodies against acetylated lysine (global), p53 acetylated at either
K373 (Ac-373) or K320 (Ac-320), CBP/ p300 and Id4. B. The total
protein lysate from cell lines as indicated was immuno-precipitated (IP)
with Id4 antibody. The immuno-precipitated lysate was then immuno-
blotted with p53 antibody (IB: p53). Representative data is shown.
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with p53. Results demonstrated that indeed mutant p53
is physically associated with CBP/P300 in DU145 + Id4
cells at significantly higher levels than mut-p53 from
DU145 cells alone (Figure 7A). These results led us to
propose a model whereby Id4 could recruit or promote
the assembly of CBP/P300 and p53.
Id4 Interacts with p53
Immuno-precipitation with Id4 and blotting with p53
demonstrated the presence of p53 in this complex in
DU145 + Id4 and LNCaP cells but not in DU145 and
LNCaP-Id4 cells suggesting that Id4 directly associates
with p53 (Figure 7B). Id4 was also co-eluted with p53
(Figure 7A) which confirms the specificity of this inter-
action and further supports the formation of a large
multi-protein complex involving Id4, CBP/p300 and p53.
These results consolidated our hypothesis that Id4 pro-
motes the recruitment of CBP/p300 on p53 to promote
acetylation and restore its biological activity.
Discussion
In this study we provide evidence that Id4 regulates p53
at two different levels: transcriptional regulation of wt-
p53 in LNCaP cells and restoration of the biological
activity of mutant p53 in DU145 cells. In this study,we focused on investigating the mechanism by which
Id4 restores the biological activity of mutant p53, clearly
an area of high interest given that mutant p53 is observed
in one third of prostate cancer [27,28] and more than 50%
of all cancers [48]. The down-regulation of wt-p53 protein
expression in the absence of Id4 in LNCaP cells (LNCaP-
Id4) is a significant observation that was not addressed in
this study. We speculate that Id4 could interact and mod-
ify the transcriptional regulators of p53 expression which
remains to be investigated.
The core domain (aa 98-303) of p53 is inherently
unstable. Point mutations in this domain promote in-
stability and unfolding, leading to decreased or com-
pletely abrogated transcriptional activity [49]. Both the
alleles of p53 in DU145 cells (p223L and V274F) carry
mutations within this core domain resulting in increased
expression of mutant p53 [22] with predominantly dena-
tured conformation. The attenuated transactivation po-
tential of p53 P223L and V274F mutants is also observed
when over-expressed in p53 null PC3 cells [50]. Hence
the mutants in DU145 cells are excellent models to
understand the mechanisms involved in promoting its
function in context of Id4 which is epigenetically silenced
in DU145 cells.
In our studies we clearly show high mutant p53 ex-
pression in DU145 cells with attenuated transactivation
potential and DNA binding activity as compared to LNCaP
cells with wt-p53. Multiple lines of evidence support the
gain of transactivation potential of mutant p53 in DU145
cell over-expressing Id4: First, mutant p53 in DU145 + Id4
cells promotes p53 dependent luciferase reporter activity,
second, mutant p53 gains DNA binding activity as demon-
strated by EMSA and direct DNA binding followed by
detection and quantitation of binding with p53 specific
antibody and thirdly, site specific binding to the respect-
ive p53 binding sites on BAX, PUMA, p21 and MDM2
P2 promoters. Studies have also shown that virtually all
tumor derived p53 mutants are unable to activate BAX
transcription but some retain the ability to activate p21
transcription [25]. However, our results suggest the p53
mutations in DU145 are incapable of trans-activating
not only p21 but BAX as well due to lack of promoter
binding. The decrease in the expression of mutant p53
in DU145 + Id4 cells as compared to DU145 could also
suggest that mutant p53 responds to the regulatory
network required to maintain its normal physiological
(compared to LNCaP cells) levels that needs to be in-
vestigated. The post-translation modifications within p53
(discussed below) can promote its function at multiple
levels by attenuating its interaction with MDM2, recruit-
ment to p53 responsive promoters and favoring nuclear
retention as observed in DU145 + Id4 cells.
The discrepancy between p21 expression at the tran-
script and protein level was also observed in LNCaP-Id4
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sponse element and RNA pol II, especially on the p21
promoter is not the sole determinant of transcriptional
repression [39] as seen in LNCaP-Id4 cells, in which p21
transcript abundance is not significantly different from
LNCaP cells. A significant decrease in p21 protein ex-
pression in LNCaP-Id4 cells could be due to increased
proteolysis. Increased MDM2 expression in LNCaP-Id4
could facilitate the binding of p21 with the proteosomal
C8-subunit [51] in a ubiquitin independent manner.
Alternatively, loss of Id4 may promote proteolysis of
p21 through ubiquitin dependent mechanisms involv-
ing e.g. Skp1/cullin/F-box (SCF) complexes that remain
to be investigated (reviewed in [52]).
Acetylation at lysine residues has emerged as a critical
post-translational modification of p53 for its function
in vivo such as growth arrest, DNA binding, stability and
co-activator recruitment ([45,46] and reviewed in [53]).
The global de-acetylation of p53 and specifically at K320
and K373 in LNCaP-Id4 cells provide strong evidence
that acetylation is a major modification required to main-
tain wild type p53 activity. Our results on mutant p53
acetylation, global and K320/ 373 specific in DU145 + Id4
are particularly novel and provide direct evidence that
mutant p53 activity can be restored by acetylation. The
increased K320 acetylation of DU145 p53 mutants is
most likely also mediated by PCAF but we did not dir-
ectly investigate this mechanism. However, a significant
observation made in this study was co-elution CBP/
P300 with wt-(LNCaP) and mutant p53 (DU145 + Id4)
and increased K373 acetylation in an Id4 dependent
manner. Moreover, co-elution of Id4 as part of this
complex with p53 antibody and co-elution of p53 with
Id4 antibody suggest that Id4 can recruit CBP/P300 on
wt-and mutant p53 to promote acetylation. Alterna-
tively, CBP/p300 could recruit Id4 to promote large
macromolecular assembly on p53 that could result in
its acetylation and increased biological activity. Thus
certain p53 mutations with some degree of conform-
ational flexibility, upon co-factor recruitment such as
Id4 and CBP/p300 could gain biological activity that is
similar to wt-p53.
Acetylation at specific lysine residues can also promote
specific p53 functional modifications: acetylation at K320
by PCAF results in increased cytoplasmic levels whereas
CBP/P300 dependent acetylation of K370/372/373 leads
to increased nuclear retention of p53 [46,47]. In contrast,
MDM2, a negative regulator of p53, actively suppresses
p300/CBP-mediated p53 acetylation in vivo and in vitro
[54]. In this study we did not investigate the role of
phosphorylation in regulating wt-or mut-p53 activity.
K373 acetylation mimic p53Q373 undergoes hyper-
phosphorylation and interacts more strongly with low
affinity pro-apoptotic promoters such as BAX. In contrast,the p53Q320 interacts efficiently with the high-affinity
p21 promoter [46]. The ChIP data demonstrating high
p53 binding on p21 promoter in DU145 + Id4 cells with
increased p53 K320 acetylation may suggest increased
phosphorylation that correlates well and further supports
acetylation dependent increase in mutant p53 activity.
As such, low MDM2 levels observed in DU145 + Id4
cells as compared to DU145 could be one of the mechan-
ism by which mutant p53 could gain its trans-activation
potential together with increased acetylation. MDM2
binds to the N-terminal end of p53 to inhibit its trans-
activation function partly by suppressing p300/CBP-
mediated p53 acetylation [54]. Acetylation also destabilizes
p53-MDM2 interaction and enables p53 mediated re-
sponse including recruitment to respective promoters
and apoptosis [38]. Studies in DU145 and LNCaP cells
using nutlin, a disruptor of p53-MDM2 interaction, sug-
gested that blocking MDM2 interaction or decreasing
its cellular levels may be sufficient to promote wt-p53
activity (LNCaP cells) but is not sufficient for promoting
mutant p53 transcriptional activity in DU145 cells [21].
In a recent study [55], Id4 expression was shown to be
regulated by mutant p53 in an E2F1 dependent manner
in breast cancer cell lines SKBR3 (p53 R175H) and
MDA-MB-231 (p53 R280K). Both these cell lines were
also shown to express Id4 [55]. Meta-analysis on clinical
samples revealed that mutant p53 breast cancer tumors
under-express Id4 suggesting an inverse correlation [56]
as seen in DU145 cells. Based on our results, we specu-
late that in the study by Fontemaggi et al., [55] Id4
could restore functional conformation of mut-p53, by
acetylation in breast cancer cell lines leading to increased
transcriptional activity. The mut-p53 in SKBR3 cells can
be restored to functional conformation by Zinc [57] fur-
ther suggesting that mut-p53 retains the flexibility to
undergo functional conformation to mimic wild type
p53 activity.
Conclusions
We provide evidence that mutant p53 in DU145 cells re-
tains the ability to undergo acetylation in the presence
of Id4. Id4, a transcriptional regulator, may promote the
p53 acetylation by recruiting CBP/p300 and/or PCAF,
independent of p53 mutations. Acetylated p53 in turn
acquires transcriptional activity through structural changes
that could possibly involve destabilization of p53-MDM2
interaction, and subsequent recruitment to p53 responsive
genes and promote apoptosis. The global acetylation pro-
moted by Id4 suggests that additional lysines such as K120
and K164, known to increase binding to specific p53
responsive genes such as PUMA could also be involved,
but remains to be investigated. Whether Id4 promotes
the activity of p53 mutants found only in DU145 cells
or it has the ability to promote transactivation potential
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next step that needs to be investigated. Nevertheless,
the acetylation mechanism is nearly universal in nature
and suggests that Id4 could promote the biological ac-
tivity of other mutants, however whether such mutants
retains sufficient structural flexibility following acetyl-
ation remains to be determined. Our results also suggest
that Id4 regulates the activity of wild type p53, a sig-
nificant observation that requires further validation in
other cell types.
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